"ErbB Receptors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of structurally-related cell-surface receptors that signal through an intrinsic PROTEIN-TYROSINE KINASE. The receptors are activated upon binding of specific ligands which include EPIDERMAL GROWTH FACTORS, and NEUREGULINS.
| Descriptor ID |
D066246
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.400.009 D12.776.543.750.630.009 D12.776.543.750.750.400.074
|
| Concept/Terms |
ErbB Receptors- ErbB Receptors
- Receptors, ErbB
- Receptors, Epidermal Growth Factor-Urogastrone
- Receptors, Epidermal Growth Factor Urogastrone
- Receptors, Epidermal Growth Factor
- EGF Receptors
- Receptors, EGF
- Epidermal Growth Factor Receptor Family Proteins
- HER Family Receptors
- Family Receptors, HER
- Receptors, HER Family
- Erb-b2 Receptor Tyrosine Kinases
- Erb b2 Receptor Tyrosine Kinases
|
Below are MeSH descriptors whose meaning is more general than "ErbB Receptors".
Below are MeSH descriptors whose meaning is more specific than "ErbB Receptors".
This graph shows the total number of publications written about "ErbB Receptors" by people in this website by year, and whether "ErbB Receptors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 6 | 1 | 7 |
| 1994 | 2 | 0 | 2 |
| 1995 | 2 | 2 | 4 |
| 1996 | 2 | 0 | 2 |
| 1997 | 2 | 0 | 2 |
| 1998 | 1 | 1 | 2 |
| 1999 | 1 | 2 | 3 |
| 2000 | 3 | 2 | 5 |
| 2001 | 0 | 1 | 1 |
| 2002 | 2 | 1 | 3 |
| 2003 | 1 | 5 | 6 |
| 2004 | 3 | 3 | 6 |
| 2005 | 9 | 7 | 16 |
| 2006 | 10 | 5 | 15 |
| 2007 | 8 | 8 | 16 |
| 2008 | 9 | 4 | 13 |
| 2009 | 11 | 4 | 15 |
| 2010 | 12 | 4 | 16 |
| 2011 | 6 | 7 | 13 |
| 2012 | 10 | 6 | 16 |
| 2013 | 6 | 3 | 9 |
| 2014 | 10 | 10 | 20 |
| 2015 | 9 | 10 | 19 |
| 2016 | 6 | 7 | 13 |
| 2017 | 6 | 6 | 12 |
| 2018 | 4 | 15 | 19 |
| 2019 | 1 | 6 | 7 |
| 2020 | 0 | 9 | 9 |
| 2021 | 0 | 11 | 11 |
| 2022 | 0 | 7 | 7 |
| 2023 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "ErbB Receptors" by people in Profiles.
-
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study. J Clin Oncol. 2023 Apr 10; 41(11):1992-1998.
-
Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study. Lung Cancer. 2023 04; 178:166-171.
-
Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial. Neuro Oncol. 2023 02 14; 25(2):339-350.
-
Exploring the Next Frontier in Non-Small-Cell Lung Cancer With High MET and Mutated Epidermal Growth Factor Receptor. J Clin Oncol. 2023 02 10; 41(5):1129-1131.
-
Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer. J Clin Oncol. 2023 02 10; 41(5):1105-1115.
-
Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial. J Thorac Oncol. 2022 09; 17(9):1086-1097.
-
Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies. Lung Cancer. 2022 08; 170:41-51.
-
The Increasing Role of Surgery in Comprehensive Treatment of Advanced Non-small Cell Lung Cancer with Targetable Mutations. Ann Surg Oncol. 2022 08; 29(8):4679-4680.
-
AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer. BMC Cancer. 2022 Apr 23; 22(1):447.
-
Adenosine Pathway in NSCLC With Molecular Drivers: Can Oncogene Addiction Translate Into Immune Addiction? J Thorac Oncol. 2022 03; 17(3):e35-e38.